A Phase 1, Randomized, Partially-Blind, Parallel-Group, Active and Placebo Controlled Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of Entecavir Extended Release (XR) in Healthy Subjects
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2017
At a glance
- Drugs Entecavir (Primary)
- Indications Hepatitis B
- Focus Pharmacokinetics
- Sponsors Aucta Pharmaceuticals
- 05 Oct 2017 Planned End Date changed from 13 Nov 2017 to 28 Feb 2018.
- 05 Oct 2017 Planned primary completion date changed from 6 Nov 2017 to 29 Dec 2017.
- 05 Oct 2017 Planned initiation date changed from 6 Sep 2017 to 20 Oct 2017.